Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Alcalá

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
Antimicrobial Agents and Chemotherapy|September 16, 1998
In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolatesF García-Garrote, E Cercenado, L Alcalá, et al.
Diagnostic Microbiology and Infectious Disease|February 17, 1999
In vitro activity of the new quinolone moxifloxacin (Bay 12-8039) against resistant gram-positive clinical isolatesL Alcalá, E Cercenado, F García-Garrote, et al.
Revista Clinica Espanola|January 24, 1998
[Current status of resistance of Staphylococcus in Spain. 4th National Study (1996). Work Group on the Study of Staphylococcus]E Cercenado, C Sánchez-Carrillo, L Alcalá, et al.
Diagnostic Microbiology and Infectious Disease|May 24, 2017
Clinical, immunological and microbiological predictors of poor outcome in Clostridium difficile infectionE Reigadas, L Alcalá, M Marín, et al.
Anaerobe|January 22, 2017
C. difficile PCR-ribotype 023 might go undetected when using ChromId C. difficile agarE Reigadas, L Alcalá, M Marín, et al.
The American Journal of Medicine|September 24, 1999
Brucella spp. peritonitisL Alcalá, P Muñoz, M Rodríguez-Créixems, et al.
Epidemiology and Infection|June 18, 2016
Role of binary toxin in the outcome of Clostridium difficile infection in a non-027 ribotype setting - CORRIGENDUME Reigadas, L Alcalá, M Marín, et al.
Anaerobe|July 30, 2019
Prediction of poor outcome in Clostridioides difficile infection: A multicentre external validation of the toxin B amplification cycleE Reigadas, L Alcalá, M Marín, et al.
Antimicrobial Agents and Chemotherapy|April 18, 2002
In vitro activity of linezolid against Clostridium difficileT Peláez, R Alonso, C Pérez, et al.
The Journal of Infection|December 3, 2014
Missed diagnosis of Clostridium difficile infection; a prospective evaluation of unselected stool samplesE Reigadas, L Alcalá, M Marín, et al.
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
Antimicrobial Agents and Chemotherapy|September 16, 1998
In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolatesF García-Garrote, E Cercenado, L Alcalá, et al.
Diagnostic Microbiology and Infectious Disease|February 17, 1999
In vitro activity of the new quinolone moxifloxacin (Bay 12-8039) against resistant gram-positive clinical isolatesL Alcalá, E Cercenado, F García-Garrote, et al.
Revista Clinica Espanola|January 24, 1998
[Current status of resistance of Staphylococcus in Spain. 4th National Study (1996). Work Group on the Study of Staphylococcus]E Cercenado, C Sánchez-Carrillo, L Alcalá, et al.
Diagnostic Microbiology and Infectious Disease|May 24, 2017
Clinical, immunological and microbiological predictors of poor outcome in Clostridium difficile infectionE Reigadas, L Alcalá, M Marín, et al.
Anaerobe|January 22, 2017
C. difficile PCR-ribotype 023 might go undetected when using ChromId C. difficile agarE Reigadas, L Alcalá, M Marín, et al.
The American Journal of Medicine|September 24, 1999
Brucella spp. peritonitisL Alcalá, P Muñoz, M Rodríguez-Créixems, et al.
Epidemiology and Infection|June 18, 2016
Role of binary toxin in the outcome of Clostridium difficile infection in a non-027 ribotype setting - CORRIGENDUME Reigadas, L Alcalá, M Marín, et al.
Anaerobe|July 30, 2019
Prediction of poor outcome in Clostridioides difficile infection: A multicentre external validation of the toxin B amplification cycleE Reigadas, L Alcalá, M Marín, et al.
Antimicrobial Agents and Chemotherapy|April 18, 2002
In vitro activity of linezolid against Clostridium difficileT Peláez, R Alonso, C Pérez, et al.
The Journal of Infection|December 3, 2014
Missed diagnosis of Clostridium difficile infection; a prospective evaluation of unselected stool samplesE Reigadas, L Alcalá, M Marín, et al.
Pageof 6